Korlym (Mifepristone) Patent Expiration, LOE Window & CMS Spending

Korlym (Mifepristone) by Corcept Therapeutics: FDA Orange Book LOE 2038-08-22, 3 AB generics, $409.6M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCorcept Therapeutics
FDA Application & PathwayN202107 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-08-22
Orange Book Patents (*PED Extensions)18 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$409.6M
2024 Medicare Part D Spend$341.8M
2024 Medicaid Spend$67.8M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 25.8% 2-yr change)